Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 33 of 40 · 1918 articles
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
Earlier use of advanced therapies and less steroid exposure could affect long-term outcomes and side-effect risk for people with newly diagnosed IBD. The study also identifies lower use of advanced therapies among...
If the appendix is a significant source of harmful IgG antibodies in ulcerative colitis, that could help explain why appendectomy sometimes reduces UC risk or severity and might influence future therapies targeting...
This study suggests that older-onset IBD is managed more conservatively and experiences fewer extraintestinal manifestations. Patients and clinicians should be aware that age can influence treatment choices and that...
Researchers are exploring new anti‑inflammatory compounds derived from food sources; this study reports a krill‑derived selenium‑chelated peptide that reduced inflammation in cells and improved outcomes in a mouse...
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Chronic pain affects many people with IBD even after inflammation is controlled, often limiting daily activities and worsening mental health. Understanding that pain can persist without active inflammation highlights the...
If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
A new patient-derived “Colon Chip” reproduces key features of Crohn’s disease and ulcerative colitis in the lab and points to fibroblasts as active drivers of inflammation and early cancer-associated changes — insights...
Researchers exploring new anti-inflammatory or antioxidant compounds for ulcerative colitis may find sanggenol L’s effects on Nrf2/HO-1 and TLR4/p65 signalling of interest. Patients should note this is early-stage,...
FMT and precision microbiota therapies target the gut ecosystem, a modifiable factor in UC. For people with UC, this review explains potential mechanisms, where FMT has shown benefit in trials, and why it is still...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Pouchitis affects a large share of patients after IPAA surgery and causes significant morbidity. Identifying pre-surgery immune, epithelial, or microbial signatures that predict pouchitis could help guide who should get...
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
Pyoderma gangrenosum is an uncommon but important extraintestinal skin complication that can occur with ulcerative colitis and may be mistaken for infection. Recognizing it matters because treatment and wound care differ...
Finding a pathogenic HMBS variant in a child with extensive ulcerative colitis suggests rare genetic conditions (like acute intermittent porphyria) can appear alongside or mimic IBD and might affect symptoms or...
People with IBD who undergo liver transplantation — especially those with PSC — can have different UC course and treatment needs because transplant immunosuppression and the liver disease itself affect the bowel.
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and CRP. The original article is from Alimentary Pharmacology & Therapeutics.
The study examines whether recommended management for rectal inflammation in UC is followed in routine care and whether following guidelines affects 12-month remission — important for patients and clinicians aiming for...
Patients and clinics are still deciding how much care can be done remotely. Knowing who prefers in-person versus remote visits helps tailor care so patients receive the visit type they need and want, and supports...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis and Procedures and surgery. The original article is from Colorectal disease : the official journal of the...
Sexual dysfunction is common in IBD and—according to this study—appears more strongly linked to psychological and demographic factors than to disease activity or muscle loss. Recognizing and treating mental-health issues...
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
Self‑management programs delivered by nurses may help people with IBD improve daily functioning, confidence in managing their condition, and quality of life even when inflammation markers don’t change. That matters...
People hospitalized with ulcerative colitis who don’t meet classic severe-disease criteria can still face meaningful colectomy risk. Using a lower CRP cutoff might help clinicians identify more high-risk patients...
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
This study suggests that subgrouping autoimmune diseases by a Traditional Chinese Medicine phenotype (Dampness ZHENG) corresponds to distinct T‑ and B‑cell receptor patterns.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from Journal of Gastroenterology and...
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
This FDA drug label explains when vitamin K (phytonadione) is indicated and how it should be dosed and monitored. People with IBD can develop vitamin K–related clotting problems because of malabsorption; the label...
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
Summer brings more social eating, travel, and foods that can trigger IBD symptoms. Practical, lower-risk treat options can help people with ulcerative colitis or Crohn’s enjoy events while reducing the chance of...
People with ulcerative colitis undergo surveillance for dysplasia because of an increased risk of colorectal cancer. This case highlights a pathology pattern (pseudocarcinomatous invasion) that can mimic invasive...
A more detailed, reproducible measure of endoscopic inflammation could better reflect total disease burden and reduce variability from human readers. That may matter for monitoring disease activity, judging treatment...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
